Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after preg...

Descripción completa

Detalles Bibliográficos
Autores principales: Toorop, Alyssa A, Rispens, Theo, Strijbis, Eva MM, van Oosten, Bob W, de Jong, Brigit A, Uitdehaag, Bernard MJ, Killestein, Joep, van Kempen, Zoé LE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report and Clinical Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795211/
https://www.ncbi.nlm.nih.gov/pubmed/34931887
http://dx.doi.org/10.1177/13524585211052168
_version_ 1784641001961291776
author Toorop, Alyssa A
Rispens, Theo
Strijbis, Eva MM
van Oosten, Bob W
de Jong, Brigit A
Uitdehaag, Bernard MJ
Killestein, Joep
van Kempen, Zoé LE
author_facet Toorop, Alyssa A
Rispens, Theo
Strijbis, Eva MM
van Oosten, Bob W
de Jong, Brigit A
Uitdehaag, Bernard MJ
Killestein, Joep
van Kempen, Zoé LE
author_sort Toorop, Alyssa A
collection PubMed
description In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID.
format Online
Article
Text
id pubmed-8795211
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87952112022-01-29 Natalizumab concentrations during pregnancy in three patients with multiple sclerosis Toorop, Alyssa A Rispens, Theo Strijbis, Eva MM van Oosten, Bob W de Jong, Brigit A Uitdehaag, Bernard MJ Killestein, Joep van Kempen, Zoé LE Mult Scler Case Report and Clinical Commentary In women with very active multiple sclerosis (MS), natalizumab can be continued during pregnancy to prevent rebound disease activity. Our aim was to evaluate changes in serum natalizumab trough concentrations during pregnancy. Blood samples of 3 patients were collected before, during, and after pregnancy. Natalizumab trough concentrations gradually decreased during pregnancy. The patient with the lowest trough concentrations during the third trimester was treated with extended interval dosing (EID). After delivery, natalizumab concentrations increased to similar levels as before pregnancy. All patients remained clinically and radiologically stable. MS neurologists should be aware of decreasing natalizumab concentrations during pregnancy, especially in patients with low initial trough concentrations and patients with EID. SAGE Publications 2021-12-21 2022-02 /pmc/articles/PMC8795211/ /pubmed/34931887 http://dx.doi.org/10.1177/13524585211052168 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report and Clinical Commentary
Toorop, Alyssa A
Rispens, Theo
Strijbis, Eva MM
van Oosten, Bob W
de Jong, Brigit A
Uitdehaag, Bernard MJ
Killestein, Joep
van Kempen, Zoé LE
Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
title Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
title_full Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
title_fullStr Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
title_full_unstemmed Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
title_short Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
title_sort natalizumab concentrations during pregnancy in three patients with multiple sclerosis
topic Case Report and Clinical Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795211/
https://www.ncbi.nlm.nih.gov/pubmed/34931887
http://dx.doi.org/10.1177/13524585211052168
work_keys_str_mv AT tooropalyssaa natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT rispenstheo natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT strijbisevamm natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT vanoostenbobw natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT dejongbrigita natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT uitdehaagbernardmj natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT killesteinjoep natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis
AT vankempenzoele natalizumabconcentrationsduringpregnancyinthreepatientswithmultiplesclerosis

Ejemplares similares